Severe childhood digestive system diseases are mostly caused by congenital digestive tract malformations, genetic metabolic diseases, acquired inflammation/infection, including biliary atresia, Hirschsprung's disease, congenital esophageal/intestinal atresia, severe/refractory inflammatory bowel disease (IBD), acute liver failure, short bowel syndrome, etc..
The global incidence is 1‰-2‰, which can lead to feeding difficulties, growth retardation, malnutrition, organ failure and even death. The digestive system of children is in the developmental stage, with weak compensatory capacity, and extremely high requirements for surgical timing, nutritional support and postoperative management.
: China has the largest number of pediatric digestive tract malformation surgeries in the world (over 50,000 cases annually). The success rate of Kasai surgery for biliary atresia exceeds 60%, and the 2-year native liver survival rate exceeds 50%, on par with top centers in Japan, Europe and America. The success rate of primary anastomosis for neonatal congenital esophageal/intestinal atresia exceeds 95%, with the minimum surgical weight for premature infants as low as 500g.
: China has the second largest annual number of pediatric liver transplantations in the world (over 1,000 cases), with over 80% living donor liver transplantation. The surgical success rate exceeds 98%, and the 5-year survival rate exceeds 95%, equal to the University of Pittsburgh Medical Center in the US. The waiting period for living donor liver transplantation is only 1-2 weeks, while it is often months to years in Europe and America, and the cost is only 1/4-1/3 of that in the US.
: China's original integrated treatment program has an intestinal rehabilitation success rate of over 80% for pediatric short bowel syndrome, avoiding intestinal transplantation. The success rate of pediatric intestinal transplantation exceeds 90%, and the 5-year survival rate exceeds 70%, reaching the international advanced level.
: Biological agents and small molecule targeted drugs for pediatric severe/refractory Crohn's disease and ulcerative colitis are widely available in China, fully synchronized with international guidelines. The original integrated traditional Chinese and Western medicine program can significantly reduce the recurrence rate, reduce hormone dosage, and improve children's growth and development, with an effective rate of over 85%.
: The popularity rate of pediatric digestive endoscopy and laparoscopic minimally invasive surgery exceeds 85%, with minimal trauma, fast recovery, and the minimum endoscopic operation age can be in the neonatal period. The whole-cycle nutritional support management can fully guarantee the growth and development of children, which is the core feature of Chinese treatment.
